Treatment of Huntington's Chorea With Amantadine
Treatment of Huntington's Chorea With Amantadine
Huntington's disease is a chronic disorder passed on through genetic autosomal dominant
 inheritance. The condition usually begins between the ages of 30 and 50 years and it is
 characterized by involuntary movements in the face and extremities, (chorea), accompanied by
 changes in behavior and gradual loss of the mental function. The disease typically ends in a
 state of disorientation, impaired memory, judgement, and intellect (dementia).

 The objective of this study is to test the effectiveness of the drug amantadine for the
 treatment of chorea associated with Huntington's disease. Amantadine is an antiviral drug
 that has been used to treat a variety of illnesses including Parkinson's disease. Amantadine
 works by attaching to special sites called NMDA (N-methyl-D-aspartate) receptors and blocking
 the normal activity of glutamate there. Glutamate is an amino acid released by brain cells
 and has been associated with the symptoms of Parkinson's disease.
The objective of this study is to evaluate the acute effects of the putative NMDA-receptor
 antagonist amantadine on chorea of patients with Huntington's disease (HD). Participants in
 this study will have mild to moderate HD associated with chorea.
All patients will carry a diagnosis of Huntington's disease confirmed by DNA testing.

 Patients will have mild to moderate disease with associated significant chorea.

 Ability to comply with study requirements and to report on their condition by telephone.

 Males and females between the ages of 18 and 82.

 No patients with the presence or history of any medical condition that can reasonably be
 expected to subject the patient to unwarranted risk.

 No patients with renal impairment (serum creatinine exceeding the upper limit of normal).

 No patients with a history of intolerance to previous exposure to amantadine.

 No patients with an MMSE of less than 18/30.

 No patients receiving other anti-chorea therapies (such as Haldol). Those receiving other
 anti-chorea therapies must stop taking these medications for at least 4 weeks prior to the
 study to be eligible.

 No pregnant women.

 Patients must practice effective means of birth control.